{"nctId":"NCT01631214","briefTitle":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","startDateStruct":{"date":"2012-05-04","type":"ACTUAL"},"conditions":["Postmenopausal Women With Osteoporosis"],"count":4093,"armGroups":[{"label":"Alendronate/Alendronate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alendronate","Drug: Placebo to Romosozumab"]},{"label":"Romosozumab/Alendronate","type":"EXPERIMENTAL","interventionNames":["Biological: Romosozumab","Drug: Alendronate","Drug: Placebo to Alendronate"]}],"interventions":[{"name":"Romosozumab","otherNames":["AMG 785","Evenity"]},{"name":"Alendronate","otherNames":["Fosamax"]},{"name":"Placebo to Romosozumab","otherNames":[]},{"name":"Placebo to Alendronate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPostmenopausal women who meet at least one of the following bone mineral density (BMD) and fracture criteria:\n\n* BMD T-score at the total hip or femoral neck of ≤ -2.50 and EITHER:\n\n  * at least 1 moderate (semiquantitative grade \\[SQ\\]2) or severe (SQ3) vertebral fracture OR\n  * at least 2 mild (SQ1) vertebral fractures OR\n* BMD T-score at the total hip or femoral neck of ≤ -2.00 and EITHER:\n\n  * at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR\n  * a fracture of the proximal femur that occurred within 3 to 24 months prior to randomization.\n\nExclusion Criteria:\n\n* History of metabolic or bone disease (except osteoporosis)\n* Use of agents affecting bone metabolism\n* Vitamin D insufficiency\n* History of solid organ or bone marrow transplants\n* Hyper- or hypocalcemia\n* Hyper- or hypothyroidism\n* Hyper- or hypoparathyroidism\n* Possible signs of intolerance to alendronate","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With New Vertebral Fractures Through Month 24","description":"All fracture assessments were performed by blinded central imaging readers.\n\nNew vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:\n\n* Grade 0 (Normal) = no fracture;\n* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);\n* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;\n* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.\n\nIncident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Clinical Fracture at the Primary Analysis","description":"All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis","description":"A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Fracture at the Primary Analysis","description":"All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24","description":"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:\n\n* Grade 0 (Normal) = no fracture;\n* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);\n* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;\n* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.\n\nIncident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis","description":"Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Hip Fracture at the Primary Analysis","description":"Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24","description":"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Fracture Through Month 24","description":"Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Nonvertebral Fracture Through Month 24","description":"A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Hip Fracture Through Month 24","description":"Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Vertebral Fracture Through Month 24","description":"A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Fracture Through Month 12","description":"Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With New Vertebral Fractures Through Month 12","description":"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:\n\n* Grade 0 (Normal) = no fracture;\n* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);\n* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;\n* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.\n\nIncident vertebral fractures were confirmed by a second independent reader.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Any Fracture Through Month 12","description":"All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Nonvertebral Fracture Through Month 12","description":"A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Hip Fracture Through Month 12","description":"Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Major Osteoporotic Fracture Through Month 12","description":"Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Vertebral Fracture Through Month 12","description":"A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"0.2"},{"groupId":"OG001","value":"15.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.1"},{"groupId":"OG001","value":"7.2","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"0.2"},{"groupId":"OG001","value":"6.0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.1"},{"groupId":"OG001","value":"13.7","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.1"},{"groupId":"OG001","value":"6.2","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.1"},{"groupId":"OG001","value":"4.9","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"0.2"},{"groupId":"OG001","value":"15.2","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.1"},{"groupId":"OG001","value":"7.2","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.2"},{"groupId":"OG001","value":"6.0","spread":"0.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":278,"n":2014},"commonTop":["Viral upper respiratory tract infection","Back pain","Arthralgia","Fall","Pain in extremity"]}}}